The Claim
Omega-3 fatty acid supplementation reduces gamma-glutamyltransferase (GGT) levels by a mean difference of 9.02 U/L in adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, taking omega-3 fatty acid supplements lowers gamma-glutamyltransferase (GGT) levels by an average of 9.02 units per liter.
See the scientific wording
Omega-3 fatty acid supplementation significantly reduces gamma-glutamyltransferase (GGT) levels by a mean difference of 9.02 U/L in adults with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, indicating a potential effect on liver cell stress or membrane integrity.
Omega-3 fatty acids enter liver cells and turn on genes that break down fat and turn off genes that make new fat. This reduces fat buildup in the liver, which decreases stress on liver cells and stabilizes their membranes, causing less GGT to leak into the blood.
What the research says
1 studyStudy: Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Taking omega-3 supplements for people with fatty liver disease helps lower a blood marker called GGT, which shows the liver is under stress. This study found that omega-3s do help reduce this marker.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.